Thrombosis in multiple myeloma (MM)

References

• Mateos MV. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev. 2010;36 Suppl 2:S24–32.
   PubMedGoogle Scholar
• Libourel EJ, Sonneveld P, van der Holt B, de Maat MP, Leebeek FW. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood. 2010;116(1):22–6.
   PubMed Web of Science ®Google Scholar
• Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, et al.. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine. 1999;78(5):285–91.
   PubMed Web of Science ®Google Scholar
• Zangari M, Barlogie B, Cavallo F, Bolejack V, Fink L, Tricot G. Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients. Blood Coagul Fibrinolysis. 2007;18:595–8.
   PubMed Web of Science ®Google Scholar
• Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R, et al.. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol. 2010;28:132–5.
   PubMed Web of Science ®Google Scholar
• Boccaccio P, Comoglio PM. Genetic link between cancer and thrombosis. J Clin Oncol. 2009;27:4827–33.
   PubMed Web of Science ®Google Scholar
• Baz R, Li L, Kottke-Marchant K, Srkalovic G, McGowan B, Yiannaki E, et al.. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 2005;80(12):1568–74.
   PubMed Web of Science ®Google Scholar
• Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood. 2006;108:403.
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Martinez-Baños D, Jalbrikowski J, Christos P, Furst J, de Sancho M, et al.. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leuk Lymphoma. 2007;48(12):2330–7.
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Martinez-Baños D. Aspirin as thromboprophylaxis in myeloma. Leuk Lymphoma. 2008;49(8):1646–7.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, et al.. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011;29(8):986–93.
   PubMed Web of Science ®Google Scholar
• Pal R, Monaghan SA, Hassett AC, Mapara MY, Schafer P, Roodman GD, et al.. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood. 2010;115(3):605–14.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Fears TR, Gridley G, Turesson I, Mellqvist UH, Björkholm M, et al.. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008;112:3582–6.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Pfeiffer RM, Björkholm M, Goldin LR, Schulman S, Blimark C, et al.. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 2010;115:4991–8.
   PubMed Web of Science ®Google Scholar
• Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, et al.. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis. 2002;13:187–92.
   PubMed Web of Science ®Google Scholar
• van Marion AM, Auwerda JJ, Minnema MC, van Oosterom R, Adelmeijer J, de Groot PG, et al.. Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thromb Haemost. 2005;94(6):1341–3.
   Web of Science ®Google Scholar
• Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol. 2006;134(4):399–405.
   PubMed Web of Science ®Google Scholar
• Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein MA, et al.. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer. 2004;101:558–66.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, et al.. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10(10):943–9.
   PubMed Web of Science ®Google Scholar
• Carrier M, Le Gal J, Tay C, Wu C, Lee AY. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost. 2011;9(4):653–66.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al.. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414–2.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al.. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11:29–3.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, et al.. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Blood. 2008;15;112(8):3107–14.
   Google Scholar
• Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, et al.. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002;100:1168–71.
   PubMed Web of Science ®Google Scholar
• Anaissie EJ, Coleman EA, Goodwin JA, Kennedy RL, Lockhart KD, Stewart CB, et al.. Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis. Cancer. 2011;118:549–57.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, et al.. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011;29(8):986–93.
   PubMed Web of Science ®Google Scholar
• Zangari M, Fink L, Zhan F, Tricot G. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. Clin Lymphoma Myeloma Leuk. 2011;11(2):228–36.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang ZG, Liu X, Hozeska A, Stagliano N, Riordan W, et al.. Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator. Thromb Haemost. 2006;95(1):166–73.
   PubMed Web of Science ®Google Scholar
• Avcu F, Ural AU, Cetin T, Nevruz O. Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro. Thromb Res. 2008;121(4):567–71.
   PubMed Web of Science ®Google Scholar
• Montiel-Manzano G, Romay-Penabad Z, Papalardo de Martinez E, Meillon-García LA, García-Latorre E, Reyes-Maldonado E, et al.. In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies. Ann NY Acad Sci. 2007;1108:540–53.
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol. 2009;27:4848–57.
   PubMed Web of Science ®Google Scholar
• Baz R, Walker E, Karam MA, Choueiri TK, Jawde RA, Bruening K, et al.. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol. 2006;17:1766–71.
   PubMed Web of Science ®Google Scholar
• Saif MW, Allegra CJ, Greenberg B. Bleeding diathesis in multiple myeloma. J Hematother Stem Cell Res. 2001;10(5):657–60.
   PubMedGoogle Scholar